MAP2K7 and acute lymphoblastic leukemia: Furthermore, MEK/ERK and p38 MAPK kinase promote T-ALL migration via interaction with the α2β1 integrin, indicating that blocking this pathway may be a promising target for T-ALL treatment [82].